Instylla's Embrace Hydrogel Embolic System Evaluated in First-In-Human Trial
March 15, 2022—Instylla, Inc., a developer of liquid embolics for peripheral vascular embolotherapy, announced that results from the first-in-hu
Source: evtoday.com
Page 43 - Ivir News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Ivir. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Ivir Today - Breaking & Trending Today
Colorectal Cancer Trials Enrolling: Could Your Patients Benefit?
Several clinical trials in colorectal cancer have recently started enrolling. Maybe one of your patients could benefit?
Source: medscape.com
Vir Biotechnology (NASDAQ:VIR) Downgraded by Zacks Investment Research
Zacks Investment Research cut shares of Vir Biotechnology (NASDAQ:VIR – Get Rating) from a buy rating to a hold rating in a research note issued to investors on Thursday, Zacks.com reports. According to Zacks, “Vir Biotechnology Inc. is a clinical-stage immunology company. It is focused on combining immunologic insights to treat and prevent serious infectious […]
Source: etfdailynews.com
Vir Biotechnology (NASDAQ:VIR) & Allogene Therapeutics (NASDAQ:ALLO) Head-To-Head Contrast
Vir Biotechnology (NASDAQ:VIR – Get Rating) and Allogene Therapeutics (NASDAQ:ALLO – Get Rating) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, analyst recommendations, institutional ownership and profitability. Analyst Ratings This is a summary of current ratings and […]
Source: etfdailynews.com
Omicron vaccine is all well and good, but the real money is on an all-in-one jab
Researchers look for alternative strategy as variant-specific vaccines seem doomed to play perpetual catch-up
Source: timeslive.co.za